SCHEMBL5010073

SCHEMBL5010073

CN1CCN(c2cc(N)cc(Cl)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 2/20 0.58
MAPT P10636 5/20 0.53
KDM4E B2RXH2 3/20 0.53
GAA P10253 2/20 0.53
PTK2B Q14289 2/20 0.53
ALDH1A1 P00352 2/20 0.53
GFER P55789 1/20 0.53
KMT2A Q03164 1/20 0.53
ESR2 Q92731 1/20 0.53
POLB P06746 1/20 0.49
RAD52 P43351 1/20 0.49
BCL2A1 Q16548 1/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
HRH4 Q9H3N8 4/20 0.45
LMNA P02545 1/20 0.45
ALOX12 P18054 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CHRM2 P08172 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2013498 0.86 ADRA2C (0.68) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL22712693 0.86 ADRA2C (0.68) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL8318081 0.86 BCL2A1 (0.59) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL5591514 0.81 ALDH1A1 (0.48) MAPTKDM4EGAAALDH1A1KMT2A
SCHEMBL12659839 0.79 BCL2A1 (0.49) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL18278152 0.79 ADRA2C (0.59) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL16795248 0.78 BCL2A1 (0.47) ADRA2CMAPTALDH1A1KMT2APOLB
SCHEMBL17027842 0.78 BCL2A1 (0.47) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL30935141 0.78 ADRA2C (0.58) ADRA2CMAPTKDM4EGAAPTK2B
SCHEMBL4717525 0.78 ADRA2C (0.58) ADRA2CMAPTKDM4EGAAPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465726-B2 Substituted pyrrolo[2.3-B]pyridines OSI PHARMACEUTICALS, INC. (US) 2008-12-16 US disclosed
US-7465726-B2 Substituted pyrrolo[2.3-B]pyridines OSI PHARMACEUTICALS, INC. (US) 2008-12-16 US disclosed
US-7465726-B2 Substituted pyrrolo[2.3-B]pyridines OSI PHARMACEUTICALS, INC. (US) 2008-12-16 US disclosed
CN-101052629-A Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds OSI PHARM INC (US) 2007-10-10 CN disclosed
EP-1797054-A2 ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2007-06-20 EP disclosed
US-20060211678-A1 Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds OSI PHARMACEUTICALS, INC. 2006-09-21 US disclosed
WO-2006017443-A2 ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211678-A1 Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds BMX, ERBB2, FRK ADRA2C 938/4885MAPT 2499/4885KDM4E 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.